rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CGEM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Hi Tech Motorcars Luxury Collection Highlights 2027 Rolls-Royce Availability and Bespoke Opportunities in Austin

      Hi Tech Motorcars Luxury Collection highlights 2027 Rolls-Royce availability in Austin, including Ghost, Cullinan, and Spectre configurations. C...

      Nov 17Business InsiderCGEM
      Cullinan Management (CGEM) Receives a Rating Update from a Top Analyst

      Tipranks Press Release.

      Nov 10The Globe and MailCGEM
      Cullinan Therapeutics: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceCGEM
      Cullinan Therapeutics earnings up next as zipalertinib nears finish line
      Nov 4Investing.comCGEM
      Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
      Nov 4Yahoo FinanceCGEM
      Learn Why The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following Trial Clearance
      Nov 1Yahoo FinanceCGEM
      Cullinan Therapeutics (CGEM) Wins Trial Clearance, Is The Upside Already Priced In?
      Oct 31Yahoo FinanceCGEM
      Cullinan Therapeutics (CGEM) Stock May Be Fully Priced Following Trial Progress
      Oct 29Yahoo FinanceCGEM
      Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

      The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

      Oct 29Yahoo FinanceCGEM
      Cullinan Therapeutics, Taiho Oncology Report 30.2% Intracranial Response Rate in Phase 2 Cancer Trial
      Oct 19Yahoo FinanceCGEM
      Cullinan Therapeutics doses first patient in phase 2 AML study
      Oct 8Investing.comCGEM
      British Museum boss 'sorry' for Bayeux Tapestry visitor issues

      Changes to how visitors see the Bayeux Tapestry exhibition were made after concerns over long queues and overcrowding.

      Oct 5BBCCGEM
      H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing
      Oct 2Investing.comCGEM
      Cullinan Therapeutics: Compelling Pullback For CLN-978’s Potential In Autoimmune Diseases

      Cullinan Therapeutics' stock pullback may be a strong entry ahead of December 2026 autoimmune updates. Read more on CGEM here.

      Sep 29Seeking AlphaCGEM
      Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

      Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter. President and CEO Nad

      Sep 28Yahoo FinanceCGEM
      Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026

      Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning...

      Sep 26Yahoo FinanceCGEM
      Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances
      Sep 24Investing.comCGEMSF
      Cullinan delays early-stage data for arthritis drug (CGEX)
      Sep 24Seeking AlphaCGEM
      Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
      Sep 24Yahoo FinanceCGEM
      Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data

      Cullinan Therapeutics stock moves after Phase 3 zipalertinib data Cullinan Therapeutics (CGEM) is back in focus after Phase 3 REZILIENT3 trial results showed zipalertinib plus chemotherapy improved progression free survival for EGFR exon 20 insertion non small cell lung cancer patients. Recent trading tells a mixed story for Cullinan Therapeutics. The share price has fallen about 22% over the past day and over the last month, and is down close to 9% over 90 days. However, the year to date...

      Sep 24Yahoo FinanceCGEM
      CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger
      Sep 24Yahoo FinanceCGEM
      Biotech Stocks Widely Dive. Here Are The Hardest Hit.

      Biotech stocks widely slumped Wednesday, with Rapport, Climb Bio and Cullinan among some of the hardest-hit names.

      Sep 23Investor's Business DailyCGEM
      Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed?
      Sep 23Yahoo FinanceCGEM
      Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

      CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, Septem

      Sep 21Yahoo FinanceCGEM
      2027 Rolls-Royce Cullinan Base Arrives with Refined Luxury and Performance in Miami

      Limited Spec Automotive announced the availability of a 2027 Rolls-Royce Cullinan Base at its Miami showroom, giving Florida collectors and luxury vehicle enthusiasts access to one of the most sought-after SUVs on the market.

      Sep 17Yahoo FinanceCGEM
      Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity?

      Cullinan Therapeutics, Inc. (NASDAQ:CGEM) disclosed detailed Phase 3 REZILIENT3 results on September 13, 2026, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Zipalertinib plus chemotherapy achieved median progression-free survival of 14.5 months, compared with 8.5 months for chemotherapy alone. Progression-free survival, or […]

      Sep 17Yahoo FinanceCGEM
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), High Tide (HITI) and Cullinan Management (CGEM)

      Detailed price information for Molina Healthcare Inc (MOH-N) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailCGEMHITIMOH
      Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call - Slideshow (NASDAQ:CGEM) 2026-09-14
      Sep 14Seeking AlphaCGEM
      Cullinan Therapeutics: The Market Shrugged At REZILIENT3, But Catalysts Await (CGEM)
      Sep 14Seeking AlphaCGEM
      Stifel reiterates Cullinan Oncology stock Buy rating on trial data
      Sep 14Investing.comCGEM
      Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
      Sep 14Yahoo FinanceCGEM
      CULLINAN PROPERTIES ANNOUNCES ITS ROCK RUN COLLECTION DEVELOPMENT IN JOLIET HAS OVER 500,000 SQUARE FEET OF SPACE IN EXECUTED DEALS OPEN OR OPENING IN 2027

      Five additional national and regional retailers announced to join DICK’S House of Sport at the ceremonial retail groundbreaking for the 1.3 million square foot super regional destinationPeoria, IL, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cullinan Properties announced it has achieved more than 500,000 square feet of executed deals current or coming to Rock Run Collection, including naming five additional national and regional retailer tenants alongside previously announced DICK’S House of Sport. The a

      Sep 11Yahoo FinanceCGEM
      Cullinan to discuss zipalertinib trial results on Monday
      Sep 10Investing.comCGEM
      SHKP posts 4.6% profit rise amid Hong Kong’s property recovery

      Hong Kong’s biggest developer reported underlying profit of HK$22.85 billion, as the city’s property market continues to recover.

      Sep 10South China Morning PostCGEM
      Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
      Sep 10Yahoo FinanceCGEM
      Bayeux Tapestry deal could pave way for Parthenon marbles loan, says British Museum head
      Aug 28Financial TimesCGEM
      Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset (NASDAQ:CGEM)

      Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers. Find out why CGEM stock is a buy.

      Aug 26Seeking AlphaCGEM

      This is the newest page. Registered accounts read further back.